The downstream targets of YTHDF1 may be related to MYC signaling regulation and T-cell differentiation, and YTHDF1 amplification resulted in reduced immune cell infiltration and significantly worse clinical features in breast cancer patients [46]. Here, MYC is linked to breast carcinoma.